---
title: 'Clinical Variables Associated with Improved Outcomes for Children and Young
  Adults Treated with CAR T Cells for B-ALL: A Decade of CAR Translation'
date: '2023-07-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37481241/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20230723180748&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Chimeric antigen receptor (CAR) T cell therapy targeting the CD19 antigen
  on B-cell acute lymphoblastic leukemia (B-ALL) has transitioned from a highly investigational
  therapy with limited access to a commercial therapy with established toxicities,
  response and survival rates, and access in numerous countries. With over a decade
  of clinical study and 5 years of commercial access, data showing associations with
  success and failure have emerged. To address CAR T cell functional limitations ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T cell therapy targeting the CD19 antigen on B-cell acute lymphoblastic leukemia (B-ALL) has transitioned from a highly investigational therapy with limited access to a commercial therapy with established toxicities, response and survival rates, and access in numerous countries. With over a decade of clinical study and 5 years of commercial access, data showing associations with success and failure have emerged. To address CAR T cell functional limitations ...